Skip to main content

Table 1 Demographics, clinical characteristics, and dose in critically ill patients receiving fluconazole, anidulafungin, and caspofungin therapy

From: Pharmacokinetic variability and exposures of fluconazole, anidulafungin, and caspofungin in intensive care unit patients: Data from multinational Defining Antibiotic Levels in Intensive care unit (DALI) patients Study

 

Fluconazole

Anidulafungin

Caspofungin

Number of patients

15

9

6

Age (years)

56 (44–82)

51 (41–66)

62 (58–72)

Weight (kg)

82 (80–90)

81 (76–92)

80 (75–85)

Male sex

11 (73)

7 (78)

5 (71)

Dose received (mg)

400 (200–400)

100

70 (loading dose)

Dose (mg/kg)

4.9 (2.3–5.0)

NA

NA

APACHE II score

22 (10–30)

18 (15–32)

22 (20–26)

SOFA score

7 (5–9)

6 (3–7)

3 (2–8)

Serum creatinine concentration (m Μ )

88 (64–203)

119 (47–228)

258 (117–286)

Measured creatinine clearance (ml/min)

45 (14–103)

62 (15–113)

NA

  1. Data are described as median [1st to 3rd quartile] or n (%).
  2. APACHE, Acute Physiology and Chronic Health Evaluation II score; SOFA, sequential Organ Failure Assessment; NA, insufficient patients with measured creatinine clearance/not applicable.